| Species |
Human |
| Protein Construction |
| Avi |
His |
Midkine (Val21-Asp143)_x000D_
Accession # P21741-1 |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
16.46 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 16.46 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene during embryogenesis, but currently viewed as a multifaceted factor contributing to both normal tissue homeostasis and disease development. Midkine is abnormally expressed at high levels in various human malignancies and acts as a mediator for the acquisition of critical hallmarks of cancer, including cell growth, survival, metastasis, migration, and angiogenesis. |
| Synonyms |
MK; ARAP; MDK; MEK; MK1; MKARAP; NEGF2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
